1. South Korea Stocks

  2. •

    Health technology

  3. •

    Biotechnology
ENCell Co., Ltd.

ENCell Co., Ltd.

KKRX:456070
4,825.00
KRW
-75.00
(-1.53%)
-1,791.51EPS
84.60BMarket Cap
ENCell Co., Ltd.
KRX:456070
(Korea Stock Exchange)

Recent

price

4,825.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2020
2021
2022
2023
2024
2025
TTM
KRW
7,618.64
20,796.58
1,543.74
1,703.8
819.53
483.83
380.24
Revenue per Share
-36,336.04
-35,003.91
-9,548
-818
-1,729
-1,482
-1,791.51
Basic EPS, GAAP
-9,564.25
-66,203.71
-2,371.6
-1,356.77
-1,220.86
-1,227.86
-1,217.33
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-254.78
-388.99
-2,552.18
4,007.37
4,474.03
3,581.66
2,532.09
Book Value per Share
-257.56
-400.85
-2,565.36
3,976.21
4,449.44
3,561.82
2,514.66
Tangible Book Value per Share
- -
- -
5
6
9
11
11
Basic Weighted Avg Shares
1,404
3,909
7,367
10,526
7,209
5,259
4,164
Sales/Revenue/Turnover
-159.99
-64.55
-126.44
-111.68
-217.54
-339.26
-435.75
Operating Margin (%)
199
890
2,964
4,239
4,498
4,705
4,719
Depreciation Expense
-6,697
-6,579
-45,567
-5,054
-15,210
-16,108
-19,620
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-476.94
-168.32
-618.5
-48.01
-210.97
-306.3
-471.16
Profit Margin (%)
-4,404
-19,481
-42,786
20,186
32,856
40,485
30,179
Working Capital
5,231
1,980
3,978
3,097
3,750
11,735
12,098
LT Debt
-2,382
-3,633
-23,836
38,016
48,168
39,404
27,857
Total Equity
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
-35.52
-36.79
-57.72
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1,280
1,011
1,040
LT Borrowings
9,003
9,243
9,766
LT Finance Leases
2,733
2,392
2,332
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
11
11
11
Market Capitalization
200,008
162,162
84,602

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
43,702
40,006
35,160
Cash, Cash Equivalents & STI
38,510
34,436
31,398
Accounts Receivable, Net
1,224
691
715
Inventories
1,123
1,630
1,929
Total Current Liabilities
3,217
4,412
4,980
Payables & Accruals
- -
- -
- -
ST Debt
1,280
1,011
1,040
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
71.52%
-18.2%
Free Cash Flow
- -
124.66%
24.26%
Net Income, GAAP
- -
141.77%
5.9%
Sales/Revenue/Turnover
- -
50.23%
-27.06%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,790
1,859
1,469
2,092
7,209
2025
1,094
1,178
1,546
1,442
5,259
2026
309
868
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-277.96
-394
-453
-482.55
-1,729
2025
-431.44
-398
-330.48
-323.03
-1,482
2026
-479.66
-656
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Amgen Inc. (NASDAQ:AMGN)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
Kodiak Sciences Inc (NASDAQ:KOD)
Business
ENCell Co. Ltd. ENCell Co., Ltd. (456070.KQ) develops and manufactures cell and gene-based biopharmaceutical products primarily focused on advanced therapies for rare and intractable diseases. The company offers contract development and manufacturing organization (CDMO) services through its ROCKET Platform, which supports multi-product GMP production for cell therapies including stem cells, CAR-T, NK cells, and exosomes, as well as gene therapies utilizing lentivirus and AAV vectors; contract quality testing (CQT) services covering raw materials, in-process controls (IPC), drug substances (DS), drug products (DP), and stability testing; and an in-house pipeline featuring EN001 (also referred to as EN00), an allogeneic Wharton's jelly-derived mesenchymal stem cell therapy targeting Charcot-Marie-Tooth disease, alongside programs for Duchenne muscular dystrophy, cancer immunotherapy, and AAV-based gene therapies. ENCell Co. Ltd. (456070.KQ) operates three PIC/S-compliant GMP facilities in South Korea, providing end-to-end solutions from research and process development to quality assurance and commercialization support for global clients in the biotechnology sector, with a target market encompassing pharmaceutical companies, research institutions, and developers of regenerative medicines. Founded in March 2018 as a spin-off from Samsung Medical Center and headquartered at WE Tower in Cheongdam-dong, Seoul, South Korea, the company leverages proprietary platform technologies like ENCT to address challenges in cell senescence, efficacy, and high-yield production. Recent developments include selection for the 2020 Seoul Business Agency Bio-Medical Technology Commercialization Support Program to advance its Duchenne muscular dystrophy treatment in collaboration with Samsung Medical Center; a strategic alliance and licensing agreement with Lucy Biotech for the EN001 mesenchymal stem cell therapy; clinical trial approval for EN001 by the Ministry of Food and Drug Safety in May 2021 following preclinical validation of nerve sheath regeneration, muscle regeneration, and safety; and ongoing expansion of GMP capabilities to secure international contracts.